drugset
drugset / Trial / NCT00581191

Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects

NCT00581191 ↗

Phase 1 Terminated 72 enrolled Wyeth is now a wholly owned subsidiary of Pfizer Solvay Pharmaceuticals · collab
RandomizedSingle-groupTriple-blindTreatment

Summary

Safety and tolerability of single oral doses in healthy subjects.

Timeline

Start
2008-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SLV-351 Unknown 0.5 mg Oral
Subject SLV-351 Unknown 1 mg Oral
Subject SLV-351 Unknown 2.5 mg Oral
Subject SLV-351 Unknown 5 mg Oral
Subject SLV-351 Unknown 10 mg Oral
Subject SLV-351 Unknown 15 mg Oral
Subject SLV-351 Unknown 20 mg Oral
Subject SLV-351 Unknown 30 mg Oral

Indications

No indication recorded.